ArticleJournal of Korean medical science2026
Dynamics of Varicella Zoster Virus-Specific Immune Reconstitution and Impact of Varicella Vaccination in Pediatric Allogeneic Hematopoietic Stem Cell Transplant Recipients.
Article in Journal of Korean medical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundVaricella-zoster virus infection poses a significant risk to pediatric hematopoietic stem cell transplant recipients owing to compromised T-cell-mediated immunity. Although varicella-zoster virus-specific T-cell-mediated immunity is crucial for preventing reactivation, its reconstitution following allogeneic hematopoietic stem cell transplant in pediatric patients remains poorly characterized.
methodsThis prospective study assessed varicella-zoster virus-specific T-cell-mediated immunity in 32 pediatric allogeneic hematopoietic stem cell transplant recipients pre-transplant and 1 and 3 months post-transplant using enzyme-linked immune absorbent spot assays. An extension study assessed varicella-zoster virus-specific T-cell-mediated immunity 2 years post-transplant in 15 recipients, including 8 after a single dose of varicella vaccination.
resultsAmong the 32 recipients (median age, 10.5 years), only one experienced post-hematopoietic stem cell transplant varicella-zoster virus infection. Median varicella-zoster virus-specific spot-forming cells were low during the first 3 months but increased significantly at 2 years (0 vs. 5.0/2.0 × 10⁵ peripheral blood mononuclear cells;
conclusionVaricella-zoster virus-specific T-cell-mediated immunity in pediatric hematopoietic stem cell transplant recipients remained low in the first 3 months but recovered significantly by 2 years post-hematopoietic stem cell transplant, with a boosting effect from varicella vaccination. Further studies are needed to assess the clinical significance of T-cell-mediated immunity and to guide personalized prevention strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.